Logo image of CRNA.OL

CIRCIO HOLDING (CRNA.OL) Stock Fundamental Analysis

Europe - Euronext Oslo - OSL:CRNA - NO0013033795 - Common Stock

1.014 NOK
-0.03 (-3.06%)
Last: 1/16/2026, 7:00:00 PM
Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to CRNA. CRNA was compared to 83 industry peers in the Biotechnology industry. CRNA may be in some trouble as it scores bad on both profitability and health. CRNA has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year CRNA was profitable.
  • In the past year CRNA has reported a negative cash flow from operations.
  • In the past 5 years CRNA reported 4 times negative net income.
  • In the past 5 years CRNA always reported negative operating cash flow.
CRNA.OL Yearly Net Income VS EBIT VS OCF VS FCFCRNA.OL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100M -200M -300M -400M

1.2 Ratios

  • CRNA has a Return On Assets of 451.20%. This is amongst the best in the industry. CRNA outperforms 100.00% of its industry peers.
Industry RankSector Rank
ROA 451.2%
ROE N/A
ROIC N/A
ROA(3y)-202.31%
ROA(5y)-129%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CRNA.OL Yearly ROA, ROE, ROICCRNA.OL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K

1.3 Margins

  • CRNA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CRNA.OL Yearly Profit, Operating, Gross MarginsCRNA.OL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100K -200K -300K -400K

More info and screens

1

2. Health

2.1 Basic Checks

  • CRNA does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, CRNA has more shares outstanding
  • The number of shares outstanding for CRNA has been reduced compared to 5 years ago.
  • The debt/assets ratio for CRNA has been reduced compared to a year ago.
CRNA.OL Yearly Shares OutstandingCRNA.OL Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
CRNA.OL Yearly Total Debt VS Total AssetsCRNA.OL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

  • CRNA has an Altman-Z score of -16.98. This is a bad value and indicates that CRNA is not financially healthy and even has some risk of bankruptcy.
  • CRNA has a worse Altman-Z score (-16.98) than 79.52% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -16.98
ROIC/WACCN/A
WACC5.45%
CRNA.OL Yearly LT Debt VS Equity VS FCFCRNA.OL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

  • CRNA has a Current Ratio of 0.50. This is a bad value and indicates that CRNA is not financially healthy enough and could expect problems in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 0.50, CRNA is doing worse than 83.13% of the companies in the same industry.
  • A Quick Ratio of 0.50 indicates that CRNA may have some problems paying its short term obligations.
  • CRNA has a Quick ratio of 0.50. This is amonst the worse of the industry: CRNA underperforms 80.72% of its industry peers.
Industry RankSector Rank
Current Ratio 0.5
Quick Ratio 0.5
CRNA.OL Yearly Current Assets VS Current LiabilitesCRNA.OL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

1

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 117.43% over the past year.
  • The Revenue for CRNA has decreased by -100.00% in the past year. This is quite bad
EPS 1Y (TTM)117.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-104.92%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • CRNA is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -25.99% yearly.
  • Based on estimates for the next years, CRNA will show a very negative growth in Revenue. The Revenue will decrease by -25.99% on average per year.
EPS Next Y-109.61%
EPS Next 2Y-41.42%
EPS Next 3Y-25.99%
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5YN/A

3.3 Evolution

CRNA.OL Yearly Revenue VS EstimatesCRNA.OL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2022 2023 2024 20M 40M 60M 80M 100M
CRNA.OL Yearly EPS VS EstimatesCRNA.OL Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2023 2024 2025 0 -20 -40 -60

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 0.36, the valuation of CRNA can be described as very cheap.
  • Compared to the rest of the industry, the Price/Earnings ratio of CRNA indicates a rather cheap valuation: CRNA is cheaper than 98.80% of the companies listed in the same industry.
  • The average S&P500 Price/Earnings ratio is at 27.47. CRNA is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 0.36
Fwd PE N/A
CRNA.OL Price Earnings VS Forward Price EarningsCRNA.OL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CRNA.OL Per share dataCRNA.OL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2

4.3 Compensation for Growth

  • CRNA's earnings are expected to decrease with -25.99% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-41.42%
EPS Next 3Y-25.99%

More info and screens

0

5. Dividend

5.1 Amount

  • CRNA does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

CIRCIO HOLDING

OSL:CRNA (1/16/2026, 7:00:00 PM)

1.014

-0.03 (-3.06%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-28
Earnings (Next)04-08
Inst Owners0.93%
Inst Owner ChangeN/A
Ins Owners14.47%
Ins Owner ChangeN/A
Market Cap145.64M
Revenue(TTM)N/A
Net Income(TTM)57.52M
Analysts85.71
Price Target3.06 (201.78%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)88.47%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE 0.36
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)2.79
EY275.15%
EPS(NY)0
Fwd EYN/A
FCF(TTM)-0.33
FCFYN/A
OCF(TTM)-0.33
OCFYN/A
SpS0
BVpS-0.09
TBVpS-0.09
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 451.2%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-202.31%
ROA(5y)-129%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.5
Quick Ratio 0.5
Altman-Z -16.98
F-Score5
WACC5.45%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)117.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-104.92%
EPS Next Y-109.61%
EPS Next 2Y-41.42%
EPS Next 3Y-25.99%
EPS Next 5YN/A
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5YN/A
EBIT growth 1Y57.49%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-255.56%
EBIT Next 3Y-25.99%
EBIT Next 5YN/A
FCF growth 1Y59.04%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y57.3%
OCF growth 3YN/A
OCF growth 5YN/A

CIRCIO HOLDING / CRNA.OL FAQ

What is the ChartMill fundamental rating of CIRCIO HOLDING (CRNA.OL) stock?

ChartMill assigns a fundamental rating of 1 / 10 to CRNA.OL.


Can you provide the valuation status for CIRCIO HOLDING?

ChartMill assigns a valuation rating of 2 / 10 to CIRCIO HOLDING (CRNA.OL). This can be considered as Overvalued.


How profitable is CIRCIO HOLDING (CRNA.OL) stock?

CIRCIO HOLDING (CRNA.OL) has a profitability rating of 1 / 10.


Can you provide the PE and PB ratios for CRNA stock?

The Price/Earnings (PE) ratio for CIRCIO HOLDING (CRNA.OL) is 0.36 and the Price/Book (PB) ratio is -11.74.


Can you provide the financial health for CRNA stock?

The financial health rating of CIRCIO HOLDING (CRNA.OL) is 1 / 10.